Capricor Therapeutics Reports $40.7M Net Loss in Q2 2026 Amid Increased R&D Expenses

Capricor Therapeutics, Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of approximately $40.7 million, compared to a net loss of $25.9 million for the same period in 2025. For the six months ending June 30, 2026, the company recorded a net loss of about $74.7 million, up from $50.3 million in the prior year. The increase in losses is attributed to heightened research and development (R&D) expenses, which rose to $28.9 million for the quarter, a 31% increase from $22.0 million in the previous year. The total R&D expenses for the first half of 2026 reached $56.2 million, marking a 37% increase compared to $41.0 million in the same period of 2025.

The company's total operating expenses for the second quarter of 2026 were approximately $42.9 million, up from $27.7 million in the same quarter of 2025. General and administrative (G&A) expenses surged to $14.1 million, a 148% increase from $5.7 million in the prior year, primarily due to increased legal and consulting costs associated with regulatory and pre-commercial initiatives. Capricor's cash, cash equivalents, and marketable securities totaled approximately $237.9 million as of June 30, 2026, a decrease from $318.1 million at the end of 2025, largely due to ongoing preparations for potential commercialization of its lead product candidate, Deramiocel.

Capricor continues to focus on the development of Deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy (DMD). The company is currently awaiting FDA approval, with a Prescription Drug User Fee Act (PDUFA) target action date set for August 22, 2026. The company has administered approximately 1,300 intravenous infusions of Deramiocel across its clinical trials involving over 200 patients. In addition to its DMD program, Capricor is advancing its exosome platform technology, which is in early-stage development.

Strategically, Capricor has entered into distribution agreements with Nippon Shinyaku for the commercialization of Deramiocel in the United States and Japan. The U.S. Distribution Agreement has faced legal challenges, with Capricor filing a motion for a preliminary injunction against Nippon Shinyaku, citing issues with the pricing structure and the adequacy of preparations for the product's launch. The company has also received an upfront payment of $12 million under the Japan Distribution Agreement, with potential additional milestone payments of up to $89 million.

Looking ahead, Capricor anticipates continued significant expenses and operating losses as it seeks to develop and commercialize Deramiocel and other product candidates. The company is actively exploring additional funding sources, including equity and debt financing, to support its operations and clinical development programs. The outcome of the FDA's review of the Biologics License Application for Deramiocel will be pivotal in determining the company's future financial trajectory and operational strategy.